Rejuvenate Biomed Started a Groundbreaking Clinical Trial and Expands for Future Growth

• Started clinical trial with lead candidate RJx-01 for treating sarcopenia
• Expands the team and moved to new offices and lab

Diepenbeek, Health Campus, Belgium, 29 March 2022 – Rejuvenate Biomed NV (“Rejuvenate”), a biomedical company developing novel combination drugs for age-related diseases, today provides an update on its development pipeline and strategy.